Volume: | 384,004 |
Day Range: | 1.36 - 1.49 |
Bid: | 1.41 |
Ask: | 1.49 |
Last Trade Time: | 6:03:40 PM EST |
Total Trades: | 1,413 |
Recent CUE News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2025 09:00:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2025 09:00:17 PM
- Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/29/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/29/2024 09:00:05 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/29/2024 09:00:03 PM
- Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference • GlobeNewswire Inc. • 11/25/2024 01:00:00 PM
- Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 11/14/2024 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 09:00:09 PM
- Cue Biopharma Announces Strategic Organizational Transition • GlobeNewswire Inc. • 11/14/2024 01:00:09 PM
- Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference • GlobeNewswire Inc. • 11/12/2024 01:00:00 PM
- Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting • GlobeNewswire Inc. • 11/08/2024 06:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 08:00:08 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/07/2024 09:07:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:00:07 PM
- Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting • GlobeNewswire Inc. • 10/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:17:01 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/27/2024 08:05:39 PM
- Cue Biopharma Announces Pricing of $12.0 Million Public Offering • GlobeNewswire Inc. • 09/27/2024 03:26:30 AM
- Cue Biopharma Announces Proposed Public Offering • GlobeNewswire Inc. • 09/27/2024 03:10:15 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/26/2024 08:32:08 PM
- Cue Biopharma Announces Proposed Public Offering • GlobeNewswire Inc. • 09/26/2024 08:27:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/10/2024 08:00:02 PM
- Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:00:04 PM
Cannabix and AlcoPro Enter MOU for Marijuana Breathalyzer Marketing • BLO • Jan 24, 2025 8:49 AM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM